You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLoxapine
Accession NumberDB00408  (APRD00574)
TypeSmall Molecule
GroupsApproved
DescriptionAn antipsychotic agent used in schizophrenia. [PubChem]
Structure
Thumb
Synonyms
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine
Cloxazepine
Loxapina
Loxapine
Loxapinum
oxilapine
External Identifiers
  • AZ-004
  • BRN 0626753
  • CL 62362
  • CL 71563
  • HF 3170
  • LW 3170
  • S 805
  • SUM 3170
  • UNII-376MYL4MAL
  • UNII-LER583670J
  • UNII-X59SG0MRYU
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdasuvePowder, metered4.5 mgRespiratory (inhalation)Ferrer Internacional S.A.2013-02-20Not applicableEu
AdasuveAerosol, powder10 mg/1Respiratory (inhalation)Teva Select Brands2014-01-22Not applicableUs
AdasuvePowder, metered9.1 mgRespiratory (inhalation)Ferrer Internacional S.A.2013-02-20Not applicableEu
AdasuvePowder, metered4.5 mgRespiratory (inhalation)Ferrer Internacional S.A.2013-02-20Not applicableEu
AdasuvePowder, metered9.1 mgRespiratory (inhalation)Ferrer Internacional S.A.2013-02-20Not applicableEu
Dom-loxapine Tablets 10mgTablet10 mgOralDominion Pharmacal1999-09-15Not applicableCanada
Dom-loxapine Tablets 25mgTablet25 mgOralDominion Pharmacal1999-09-15Not applicableCanada
Dom-loxapine Tablets 50mgTablet50 mgOralDominion Pharmacal1999-09-15Not applicableCanada
Dom-loxapine Tablets 5mgTablet5 mgOralDominion Pharmacal1999-09-15Not applicableCanada
Loxapac - Tab 10mgTablet10 mgOralWyeth Ayerst Canada Inc.1997-09-242002-02-06Canada
Loxapac - Tab 50mgTablet50 mgOralWyeth Ayerst Canada Inc.1997-02-042001-05-22Canada
Loxapac - Tab 5mgTablet5 mgOralWyeth Ayerst Canada Inc.1997-02-042002-07-31Canada
Loxapac ImLiquid50 mgIntramuscularSandoz Canada Incorporated1997-06-13Not applicableCanada
Loxapac Inj 50mg/mlLiquid50 mgIntramuscularLederle Cyanamid Canada Inc.1980-12-311997-08-14Canada
Loxapac Oral Concentrate-liq 25mg/mlLiquid25 mgOralWyeth Ayerst Canada Inc.1996-11-152001-09-19Canada
Loxapac Orl Conc 25mg/mlLiquid25 mgOralLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Loxapac Tab 10mgTablet13.6 mgOralLederle Cyanamid Canada Inc.1975-12-311999-04-12Canada
Loxapac Tab 25mgTablet34 mgOralLederle Cyanamid Canada Inc.1975-12-311997-08-14Canada
Loxapac Tab 50mgTablet68 mgOralLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Loxapac Tab 5mgTablet6.8 mgOralLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Loxapac Tablets - 25 mgTablet25 mgOralWyeth Ayerst Canada Inc.1997-06-132002-03-19Canada
Loxapine Hydrochloride Im Injection 50mg/mlLiquid50 mgIntramuscularWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Hydrochloride Oral Concentrate 25mg/mlLiquid25 mgOralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 10mgTablet10 mgOralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 25mgTablet25 mgOralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 5 mgTablet5 mgOralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 50mgTablet50 mgOralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine-10Tablet10 mgOralPro Doc Limitee1998-09-012010-07-13Canada
Loxapine-25Tablet25 mgOralPro Doc Limitee1998-09-012010-07-13Canada
Loxapine-5Tablet5 mgOralPro Doc Limitee1998-09-012010-07-13Canada
Loxapine-50Tablet50 mgOralPro Doc Limitee1998-09-012010-07-13Canada
Nu-loxapineTablet50 mgOralNu Pharm Inc1998-07-132012-09-04Canada
Nu-loxapineTablet5 mgOralNu Pharm Inc1998-07-022012-09-04Canada
Nu-loxapineTablet10 mgOralNu Pharm Inc1998-07-022012-09-04Canada
Nu-loxapineTablet25 mgOralNu Pharm Inc1998-07-062012-09-04Canada
PHL-loxapineTablet50 mgOralPharmel Inc1998-02-162016-10-25Canada
PHL-loxapineTablet2.5 mgOralPharmel Inc2004-07-222016-10-25Canada
PHL-loxapineSolution25 mgOralPharmel Inc2004-07-222016-10-25Canada
PHL-loxapineTablet5 mgOralPharmel Inc1998-02-162016-10-25Canada
PHL-loxapineTablet10 mgOralPharmel Inc1998-02-162016-10-25Canada
PHL-loxapineTablet25 mgOralPharmel Inc1998-02-162016-10-25Canada
XylacTablet2.5 mgOralPendopharm Division Of De Pharmascience Inc2000-10-05Not applicableCanada
XylacTablet25 mgOralPendopharm Division Of De Pharmascience Inc1997-07-08Not applicableCanada
XylacTablet50 mgOralPendopharm Division Of De Pharmascience Inc1998-04-16Not applicableCanada
XylacTablet5 mgOralPendopharm Division Of De Pharmascience Inc1997-06-13Not applicableCanada
XylacSolution25 mgOralPendopharm Division Of De Pharmascience Inc1998-12-03Not applicableCanada
XylacTablet10 mgOralPendopharm Division Of De Pharmascience Inc1998-04-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-loxapineTablet50 mgOralApotex Inc1998-03-30Not applicableCanada
Apo-loxapineTablet5 mgOralApotex Inc1998-03-30Not applicableCanada
Apo-loxapineTablet10 mgOralApotex Inc1998-03-30Not applicableCanada
Apo-loxapineTablet25 mgOralApotex Inc1998-03-30Not applicableCanada
LoxapineCapsule50 mg/1OralWatson Laboratories, Inc.1988-06-15Not applicableUs
LoxapineCapsule25 mg/1OralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
LoxapineCapsule10 mg/1OralAmerican Health Packaging2013-06-24Not applicableUs
LoxapineCapsule5 mg/1OralLannett Company, Inc.2011-09-26Not applicableUs
LoxapineCapsule50 mg/1OralEpic Pharma, LLC2015-01-02Not applicableUs
LoxapineCapsule5 mg/1OralClinical Solutions Wholesale1988-06-15Not applicableUs
LoxapineTablet50 mg/1OralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
LoxapineCapsule5 mg/1OralWatson Laboratories, Inc.1988-06-15Not applicableUs
LoxapineCapsule25 mg/1OralMylan Institutional Inc.2004-12-15Not applicableUs
LoxapineTablet5 mg/1OralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
LoxapineCapsule5 mg/1OralEpic Pharma, LLC2015-01-02Not applicableUs
LoxapineCapsule10 mg/1OralLannett Company, Inc.2011-09-26Not applicableUs
LoxapineCapsule50 mg/1OralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
LoxapineCapsule25 mg/1OralAmerican Health Packaging2013-06-24Not applicableUs
LoxapineCapsule5 mg/1OralClinical Solutions Wholesale, Llc2016-06-29Not applicableUs
LoxapineCapsule10 mg/1OralClinical Solutions Wholesale1988-06-15Not applicableUs
LoxapineCapsule10 mg/1OralWatson Laboratories, Inc.1988-06-15Not applicableUs
LoxapineCapsule50 mg/1OralMylan Institutional Inc.2004-12-15Not applicableUs
LoxapineCapsule10 mg/1OralEpic Pharma, LLC2015-01-02Not applicableUs
LoxapineTablet10 mg/1OralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
LoxapineCapsule25 mg/1OralLannett Company, Inc.2011-09-26Not applicableUs
LoxapineCapsule50 mg/1OralAmerican Health Packaging2013-06-24Not applicableUs
LoxapineCapsule5 mg/1OralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
LoxapineCapsule25 mg/1OralClinical Solutions Wholesale1988-06-15Not applicableUs
LoxapineCapsule25 mg/1OralWatson Laboratories, Inc.1988-06-15Not applicableUs
LoxapineCapsule10 mg/1OralREMEDYREPACK INC.2014-05-21Not applicableUs
LoxapineCapsule25 mg/1OralEpic Pharma, LLC2015-01-02Not applicableUs
LoxapineTablet25 mg/1OralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
LoxapineCapsule50 mg/1OralLannett Company, Inc.2011-09-26Not applicableUs
LoxapineCapsule10 mg/1OralMylan Institutional Inc.2004-12-15Not applicableUs
LoxapineCapsule5 mg/1OralCarilion Materials Management1988-06-15Not applicableUs
LoxapineCapsule10 mg/1OralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
LoxapineCapsule50 mg/1OralClinical Solutions Wholesale1988-06-15Not applicableUs
Loxapine SuccinateCapsule25 mg/1OralREMEDYREPACK INC.2011-08-15Not applicableUs
Loxapine SuccinateCapsule5 mg/1OralREMEDYREPACK INC.2011-09-15Not applicableUs
Loxapine SuccinateCapsule5 mg/1OralREMEDYREPACK INC.2010-11-302016-10-13Us
Loxapine SuccinateCapsule50 mg/1OralREMEDYREPACK INC.2011-09-152016-11-10Us
Loxapine SuccinateCapsule10 mg/1OralREMEDYREPACK INC.2010-12-08Not applicableUs
Loxapine SuccinateCapsule50 mg/1OralREMEDYREPACK INC.2011-04-26Not applicableUs
LoxitaneCapsule5 mg/1OralWatson Pharma, Inc.1988-06-15Not applicableUs
LoxitaneCapsule10 mg/1OralWatson Pharma, Inc.1988-06-15Not applicableUs
LoxitaneCapsule25 mg/1OralWatson Pharma, Inc.1988-06-15Not applicableUs
LoxitaneCapsule50 mg/1OralWatson Pharma, Inc.1988-06-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CloxazepineNot Available
LopacNewai Chem
LosagenPatron
LoxapacWyeth
RosupSwiss Pharm
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Loxapine hydrochloride
ThumbNot applicableDBSALT001429
Loxapine succinate
ThumbNot applicableDBSALT001194
Categories
UNIILER583670J
CAS number1977-10-2
WeightAverage: 327.808
Monoisotopic: 327.11383992
Chemical FormulaC18H18ClN3O
InChI KeyXJGVXQDUIWGIRW-UHFFFAOYSA-N
InChI
InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
IUPAC Name
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2
Pharmacology
IndicationFor the management of the manifestations of psychotic disorders such as schizophrenia
Structured Indications
PharmacodynamicsLoxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Pharmacologically, Loxapine is a tranquilizer for which the exact mode of action has not been established, however, it is believed that by antagonising dopamine and serotonin receptors, there is a marked cortical inhibition which can manifest as tranquilization and suppression of aggression.
Mechanism of actionLoxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 1AProteinunknown
binder
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
binder
HumanP28222 details
5-hydroxytryptamine receptor 1DProteinunknown
binder
HumanP28221 details
5-hydroxytryptamine receptor 1EProteinunknown
binder
HumanP28566 details
5-hydroxytryptamine receptor 3AProteinunknown
binder
HumanP46098 details
5-hydroxytryptamine receptor 5AProteinunknown
binder
HumanP47898 details
5-hydroxytryptamine receptor 6Proteinunknown
binder
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
binder
HumanP34969 details
Alpha-1A adrenergic receptorProteinunknown
binder
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
binder
HumanP35368 details
Alpha-2A adrenergic receptorProteinunknown
binder
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
binder
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
binder
HumanP18825 details
Beta-1 adrenergic receptorProteinunknown
binder
HumanP08588 details
Muscarinic acetylcholine receptor M1Proteinunknown
binder
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
binder
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
binder
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
binder
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
binder
HumanP08912 details
D(1) dopamine receptorProtein groupunknown
binder
Humannot applicabledetails
D(3) dopamine receptorProteinunknown
binder
HumanP35462 details
D(4) dopamine receptorProteinunknown
binder
HumanP21917 details
D(1B) dopamine receptorProteinunknown
binder
HumanP21918 details
Histamine H1 receptorProteinunknown
binder
HumanP35367 details
Histamine H2 receptorProteinunknown
binder
HumanP25021 details
Histamine H4 receptorProteinunknown
binder
HumanQ9H3N8 details
Sodium-dependent serotonin transporterProteinunknown
binder
HumanP31645 details
Sodium-dependent noradrenaline transporterProteinunknown
binder
HumanP23975 details
Sodium-dependent dopamine transporterProteinunknown
binder
HumanQ01959 details
Related Articles
AbsorptionSystemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationMetabolites are excreted in the urine in the form of conjugates and in the feces unconjugated.
Half lifeOral-4 hours
ClearanceNot Available
ToxicityLD50=65 mg/kg (Orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Loxapine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineLoxapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineLoxapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineLoxapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineLoxapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aceprometazine.Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Loxapine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Loxapine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Loxapine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Alfentanil.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Loxapine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Loxapine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loxapine.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Amantadine.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Loxapine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Loxapine is combined with Amperozide.Experimental
AmphetamineLoxapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Apomorphine.Approved, Investigational
ArformoterolThe risk or severity of adverse effects can be increased when Arformoterol is combined with Loxapine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Azaperone.Vet Approved
AzelastineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Loxapine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Loxapine is combined with Baclofen.Approved
BambuterolThe risk or severity of adverse effects can be increased when Bambuterol is combined with Loxapine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.Illicit
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Loxapine.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Loxapine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Loxapine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Benzocaine.Approved
BenzphetamineLoxapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Loxapine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Brotizolam.Approved, Withdrawn
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Loxapine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Loxapine.Approved, Investigational
BuprenorphineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Loxapine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loxapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Loxapine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Loxapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Loxapine.Approved
CarbamazepineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Loxapine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Loxapine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorphenamine.Approved
ChlorphentermineLoxapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorzoxazone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Loxapine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Loxapine.Approved
ClemastineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Loxapine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Loxapine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Loxapine is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Loxapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Loxapine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclobenzaprine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loxapine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Loxapine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Loxapine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineLoxapine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Loxapine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylpropionLoxapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Loxapine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loxapine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Loxapine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Loxapine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Loxapine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Loxapine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Loxapine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Loxapine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Loxapine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Loxapine.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Loxapine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Loxapine is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Loxapine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Loxapine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Loxapine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loxapine.Approved
EthanolLoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loxapine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Loxapine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Loxapine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Loxapine.Approved
FentanylThe risk or severity of adverse effects can be increased when Loxapine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Loxapine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunarizine.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Loxapine.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Loxapine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Loxapine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Loxapine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Loxapine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Loxapine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Loxapine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Loxapine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Loxapine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Loxapine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Loxapine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Loxapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Loxapine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Loxapine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Loxapine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Loxapine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Hexobarbital.Approved
HydrocodoneLoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.Approved, Illicit
Hydroxyamphetamine hydrobromideLoxapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Indacaterol is combined with Loxapine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Loxapine is combined with Indalpine.Investigational, Withdrawn
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Loxapine.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Loxapine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Isoflurane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Loxapine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Loxapine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Loxapine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Loxapine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Levorphanol.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Levosalbutamol is combined with Loxapine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Loxapine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Loxapine.Approved, Investigational
LisdexamfetamineLoxapine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Loxapine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Lorazepam.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Loxapine is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Loxapine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Loxapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Melperone.Approved
MephedroneLoxapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineLoxapine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.Approved, Illicit
MequitazineLoxapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Loxapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineLoxapine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Loxapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Methohexital.Approved
MethotrimeprazineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.Approved, Investigational
MetyrosineLoxapine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Loxapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved, Investigational
MirtazapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDALoxapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Loxapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Molindone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Loxapine.Approved, Vet Approved
MontelukastThe risk or severity of adverse effects can be increased when Montelukast is combined with Loxapine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Loxapine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Loxapine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Loxapine.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Loxapine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Loxapine.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Olodaterol is combined with Loxapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olopatadine.Approved
OmalizumabThe risk or severity of adverse effects can be increased when Omalizumab is combined with Loxapine.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Loxapine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Loxapine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Loxapine.Approved
OrphenadrineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Loxapine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.Approved
ParaldehydeLoxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Loxapine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Loxapine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Loxapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Loxapine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenoxyethanol.Approved
PhentermineLoxapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Loxapine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Pirbuterol is combined with Loxapine.Approved
PiribedilThe therapeutic efficacy of Loxapine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Loxapine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Loxapine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Loxapine is combined with Pomalidomide.Approved
PramipexoleLoxapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pramocaine.Approved
PranlukastThe risk or severity of adverse effects can be increased when Pranlukast is combined with Loxapine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Loxapine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Loxapine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Loxapine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Loxapine is combined with PSD502.Investigational
PseudoephedrineLoxapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Loxapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Loxapine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Loxapine is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Loxapine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Loxapine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Loxapine is combined with Ritanserin.Investigational
RitobegronLoxapine may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Loxapine.Approved
RoflumilastThe risk or severity of adverse effects can be increased when Roflumilast is combined with Loxapine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Romifidine.Vet Approved
RopiniroleLoxapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine.Approved
RotigotineLoxapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Loxapine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Loxapine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Loxapine is combined with Sage 547.Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Salbutamol is combined with Loxapine.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Loxapine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Loxapine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Loxapine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Loxapine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Loxapine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Loxapine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Loxapine.Approved, Investigational
SuvorexantLoxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Loxapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Loxapine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Loxapine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Loxapine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Loxapine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Loxapine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetrodotoxin.Investigational
ThalidomideLoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Loxapine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Loxapine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Loxapine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Loxapine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Trazodone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Loxapine.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triprolidine.Approved
TulobuterolThe risk or severity of adverse effects can be increased when Tulobuterol is combined with Loxapine.Investigational
Uc1010The risk or severity of adverse effects can be increased when Loxapine is combined with Uc1010.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Loxapine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Loxapine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Loxapine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Loxapine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Loxapine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Loxapine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Loxapine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Xylazine.Vet Approved
ZafirlukastThe risk or severity of adverse effects can be increased when Zafirlukast is combined with Loxapine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Loxapine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Loxapine is combined with Ziconotide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Loxapine.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Loxapine.Approved, Investigational
ZolpidemLoxapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Loxapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.
References
Synthesis Reference

U.S. Patents 3,412,193; 3,546,226.

US3412193
General References
  1. Glazer WM: Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999;60 Suppl 10:42-6. [PubMed:10340686 ]
  2. Cheung SW, Tang SW, Remington G: Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1991 Mar 8;564(1):213-21. [PubMed:1860915 ]
External Links
ATC CodesN05AH01
AHFS Codes
  • 28:16.08.92
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.9801
Caco-2 permeable+0.5531
P-glycoprotein substrateSubstrate0.8545
P-glycoprotein inhibitor IInhibitor0.8525
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7084
CYP450 2C9 substrateNon-substrate0.7331
CYP450 2D6 substrateSubstrate0.7155
CYP450 3A4 substrateSubstrate0.6309
CYP450 1A2 substrateInhibitor0.8159
CYP450 2C9 inhibitorNon-inhibitor0.8755
CYP450 2D6 inhibitorInhibitor0.7543
CYP450 2C19 inhibitorNon-inhibitor0.6217
CYP450 3A4 inhibitorNon-inhibitor0.9393
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6968
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8743
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3057 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5701
hERG inhibition (predictor II)Inhibitor0.6141
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Watson laboratories inc
  • Actavis totowa llc
  • Mylan pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, powderRespiratory (inhalation)10 mg/1
Powder, meteredRespiratory (inhalation)4.5 mg
Powder, meteredRespiratory (inhalation)9.1 mg
LiquidIntramuscular50 mg
LiquidOral25 mg
TabletOral13.6 mg
TabletOral34 mg
TabletOral68 mg
TabletOral6.8 mg
CapsuleOral10 mg/1
CapsuleOral25 mg/1
CapsuleOral5 mg/1
CapsuleOral50 mg/1
TabletOral10 mg/1
TabletOral25 mg/1
TabletOral5 mg/1
TabletOral50 mg/1
SolutionOral25 mg
TabletOral10 mg
TabletOral2.5 mg
TabletOral25 mg
TabletOral5 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Loxapac 50 mg/ml7.05USD ml
Loxitane 50 mg capsule4.04USD capsule
Loxitane 25 mg capsule3.09USD capsule
Loxapine 50 mg capsule2.57USD capsule
Loxitane 10 mg capsule2.04USD capsule
Loxapine 25 mg capsule1.92USD capsule
Loxitane 5 mg capsule1.58USD capsule
Loxapine 10 mg capsule1.27USD capsule
Loxapine Succinate 5 mg capsule1.03USD capsule
Loxapine 5 mg capsule0.99USD capsule
Pms-Loxapine 50 mg Tablet0.54USD tablet
Pms-Loxapine 25 mg Tablet0.41USD tablet
Pms-Loxapine 10 mg Tablet0.26USD tablet
Pms-Loxapine 5 mg Tablet0.16USD tablet
Pms-Loxapine 2.5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6716416 No2002-05-202022-05-20Us
US7052679 No2001-10-262021-10-26Us
US7078020 No2001-10-262021-10-26Us
US7090830 No2001-10-262021-10-26Us
US7458374 No2004-08-182024-08-18Us
US7537009 No2004-10-282024-10-28Us
US7585493 No2001-10-262021-10-26Us
US7601337 No2001-10-262021-10-26Us
US8074644 No2002-07-252022-07-25Us
US8173107 No2001-10-262021-10-26Us
US8235037 No2001-10-262021-10-26Us
US8387612 No2006-10-232026-10-23Us
US8955512 No2001-10-262021-10-26Us
US8991387 No2004-05-212024-05-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point109-111 °CU.S. Patents 3,412,193; 3,546,226.
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.103 mg/mLALOGPS
logP3.18ALOGPS
logP3.46ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)7.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area28.07 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity95.11 m3·mol-1ChemAxon
Polarizability34.99 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-7590000000-118f30ca0699bf2b3d2eView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxazepines. These are compounds containing a dibenzoxazepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazepines
Sub ClassDibenzoxazepines
Direct ParentDibenzoxazepines
Alternative Parents
Substituents
  • Dibenzoxazepine
  • Diaryl ether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Chlorobenzene
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Lee T, Tang SW: Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85. [PubMed:6239298 ]
  2. Hjerde E, Dahl SG, Sylte I: Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. Eur J Med Chem. 2005 Feb;40(2):185-94. [PubMed:15694653 ]
  3. Kalkman HO, Neumann V, Nozulak J, Tricklebank MD: Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur J Pharmacol. 1998 Feb 19;343(2-3):201-7. [PubMed:9570468 ]
  4. Froimowitz M, Cody V: Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. J Med Chem. 1993 Jul 23;36(15):2219-27. [PubMed:8101879 ]
  5. Froimowitz M, Cody V: The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists. Drug Des Discov. 1997 Aug;15(2):63-81. [PubMed:9342550 ]
  6. Lang AE, Sandor P, Duff J: Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. [PubMed:8665533 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Li Z, Ichikawa J, Meltzer HY: A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2003 May;167(3):315-23. Epub 2003 Mar 28. [PubMed:12664192 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):226-32. [PubMed:10991983 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.
Gene Name:
HTR5A
Uniprot ID:
P47898
Molecular Weight:
40254.69 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. PDSP Ki Database [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:39